Molecular Partners AG downgraded by RBC Capital Mkts
$MOLN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
RBC Capital Mkts downgraded Molecular Partners AG from Outperform to Sector Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2022 | Outperform → Sector Perform | RBC Capital Mkts | |
| 8/29/2022 | $30.00 → $8.00 | Outperform → Mkt Perform | SVB Leerink |
| 5/25/2022 | Underperform → Neutral | Credit Suisse | |
| 4/27/2022 | Neutral → Underperform | Credit Suisse |
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host conference call today, November 12 at 10AM ET (4PM CET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company de
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM Induced significant tumor regression in vivo without causing systemic cytokine release, indicating favorable safety profile ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "C
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will present updated data from a Phase 1/2a trial of MP0533, a novel, multispecific T cell engager for acute myeloid leukemia (AML) patients, in a poster at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida, and online. The poster will outline latest results of this
RBC Capital Mkts downgraded Molecular Partners AG from Outperform to Sector Perform
SVB Leerink downgraded Molecular Partners AG from Outperform to Mkt Perform and set a new price target of $8.00 from $30.00 previously
Credit Suisse upgraded Molecular Partners AG from Underperform to Neutral
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company's Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug dev
Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells Phase 1 IND for MP0712 filed, clinical trial initiation expected before end-2025 in US with initial data expected in 2026 Molecular Partners to host conference call today, November 12 at 10AM ET (4PM CET) ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company de
MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first radio-DARPin program MP0712 and initiation of Phase 1 trial expected by end 2025; update on early imaging work planned in Q4 2025; expanded strategic radiotherapy partnership with Orano MedAppointed Martin Steegmaier, Ph.D. as CSO and member of Executive CommitteeCash and cash equivalents and short-term time deposits total of CHF 114 million as of June 30, 2025, extending runway into 2028. ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 25, 2025 (GL
Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strategic partnership with Orano Med expanded from four to ten programsData from dosing cohort 8 in Phase 1/2a trial of MP0533 demonstrate increased rates and depth of responses; study protocol amendment now approved, and dosing cohort 9 enrollment initiated, additional data expected in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53
SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13D - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13G/A - MOLECULAR PARTNERS AG (0001745114) (Subject)